Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20000082HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20007360HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20027601HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20027588HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20015105HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20019576HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20019577HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS20030913HPVENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TVIS44013030HTLV-1ENSG00000068078.20protein_codingFGFR3YesNo2261P22607
Q0IJ44
TCGA Plot Options
Drug Information
GeneFGFR3
DrugBank IDDB08901
Drug NamePonatinib
Target IDBE0002133
UniProt IDP22607
Regulation Typeinhibitor
PubMed IDs23468082
CitationsGozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7.
GroupsApproved; Investigational
Direct ClassificationBenzanilides
SMILESCN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1
PathwaysPonatinib Inhibition of BCR-ABL
PharmGKBPA165980594
ChEMBLCHEMBL1171837